Evolution Research Group (ERG) is comprised of 13 wholly owned clinical research units and an affiliated site network. The company is backed by the Chicago-based private equity (PE) firm Linden Capital Partners.
The company this week acquired Rochester, NY-based Finger Lakes Clinical Research (FLCR).
Founded in 2002 and directed by Principal Investigator Sarah D. Atkinson, MD, FLCR specializes in pediatric and adult central nervous system (CNS) clinical trials.
ERG Chief Business Officer Dr. Paul Greene told us the company is excited to add FLCR to its “growing family” of leading clinical research centers.
Greene said FLCR is “highly complementary” to the ERG portfolio and will significantly augment ERG’s expertise in pediatrics.
“We believe that pediatric clinical trials will continue to be a focus of regulators as they pay more and more attention to the use of medications in younger populations. The addition of Dr. Atkinson and FLCR to the ERG family put ERG in strong position to deliver in this emerging pediatric segment of clinical research,” he explained.
Integration of FLCR into the ERG portfolio is underway, said Greene.
He added, “The focus of this is to centralize much of the business operations, not only making for cost efficiencies but also for freeing the time of the staff at FLCR to focus on patient care, patient recruitment, and operational excellence.”
Financial terms were not disclosed.